SYSTM Wealth Solutions LLC Decreases Stake in GSK plc (NYSE:GSK)

SYSTM Wealth Solutions LLC lowered its position in shares of GSK plc (NYSE:GSK) by 43.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,324 shares of the pharmaceutical company’s stock after selling 1,807 shares during the period. SYSTM Wealth Solutions LLC’s holdings in GSK were worth $90,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Register Financial Advisors LLC acquired a new position in shares of GSK during the 1st quarter worth about $31,000. Ashton Thomas Private Wealth LLC acquired a new position in GSK in the second quarter valued at approximately $37,000. Richardson Financial Services Inc. purchased a new position in GSK in the fourth quarter valued at approximately $40,000. PrairieView Partners LLC acquired a new stake in GSK during the second quarter worth approximately $47,000. Finally, Triad Wealth Partners LLC purchased a new stake in shares of GSK during the 2nd quarter worth approximately $49,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK stock opened at $41.65 on Friday. The stock’s 50-day moving average price is $41.36 and its 200 day moving average price is $41.71. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $86.32 billion, a PE ratio of 15.09, a price-to-earnings-growth ratio of 1.41 and a beta of 0.66. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%. As a group, equities research analysts forecast that GSK plc will post 4.15 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be issued a dividend of $0.3843 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a yield of 3.69%. The ex-dividend date of this dividend is Friday, August 16th. GSK’s dividend payout ratio is currently 54.71%.

Analysts Set New Price Targets

A number of research analysts recently commented on GSK shares. Jefferies Financial Group increased their target price on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. Berenberg Bank upgraded GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Finally, The Goldman Sachs Group started coverage on GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.